2. Academic Validation
  3. N6-methyladenine RNA Methylation Epigenetic Modification and Kidney Diseases

N6-methyladenine RNA Methylation Epigenetic Modification and Kidney Diseases

  • Kidney Int Rep. 2022 Oct 17;8(1):36-50. doi: 10.1016/j.ekir.2022.10.009.
Junjun Luan 1,  Jeffrey B Kopp 2,  Hua Zhou 1
Affiliations

Affiliations

  • 1 Department of Nephrology, Shengjing Hospital of China Medical University, Shenyang, China.
  • 2 Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health, Bethesda, Maryland, USA.
PMID: 36644366 DOI: 10.1016/j.ekir.2022.10.009
Abstract

RNA methylation modification is a rapidly developing field in Epigenetics. N6-methyladensine (m6A) is the most common internal modification in eukaryotic mRNA. m6A group regulates RNA splicing, stability, translocation, and translation. Enzymes catalyzing this process were termed as writers, erasers, and readers. Recent studies have focused on exploring the role of RNA methylation in human diseases. RNA methylation modifications, particularly m6A, play important roles in the pathogenesis of kidney diseases. In this review, we provide a brief description of m6A and summarize the impact of m6A on acute and chronic kidney disease (CKD) and possible future study directions for this research.

Keywords

AKD; AKI; CKD; eraser; reader; writer.

Figures
Products